Allogeneic myeloablative haematopoietic stem cell transplantation (HSCT) is challenged by severe adverse events, as cytotoxic effects of the conditioning may result in systemic inflammation, leaky epithelial barriers and organ toxicities, contributing to treatment-related morbidity and mortality. We hypothesised that insulin-like growth factor-1 (IGF-1), a mediator of growth and proliferation of various tissues, may attenuate chemotherapy-induced tissue damage after HSCT. We prospectively measured plasma levels of IGF-1 and its binding protein 3 (IGFBP-3) in 41 patients undergoing myeloablative HSCT. IGF-1 and IGFBP-3 levels were inversely correlated with C-reactive protein and interleukin-6 levels post HSCT. In multivariate analyses, low levels of IGF-1 and IGFBP-3 before conditioning were associated with increased risk of developing sinusoidal obstruction syndrome (SOS; OR = 5.00 per 1 SDS decrease in IGF-1 (95% CI: 1.45-16.67), P = 0.011 and OR = 5.00 (1.37-20.00), P = 0.015, respectively). Furthermore, low pre-transplant levels of IGF-1 and IGFBP-3 were associated with increased fluid retention during the first 21 days post transplant (OR = 7.69 (95% CI: 1.59-33.33), P = 0.012, and OR = 2.94 (1.03-8.33), P = 0.045). These data suggest that high levels of IGF-1 and IGFBP-3 may have a protective effect against fluid retention and SOS, possibly by attenuating systemic inflammation, and may prove useful as predictive biomarkers of SOS.
INTRODUCTION
Allogeneic myeloablative haematopoietic stem cell transplantation (HSCT) has improved survival in patients with haematological cancers, but remains challenged by severe adverse events, contributing to treatment-related morbidity and mortality. 1 The intestinal epithelium is highly sensitive to cytotoxic damage from chemotherapy, resulting in a dysregulated mucosal barrier with increased permeability, and translocation of bacterial products. This is assumed to induce acute toxic reactions including damage to healthy tissues along with systemic immune activation and alloreactivity driving acute GvHD (aGvHD). [1] [2] [3] Chemotherapy-induced disruption of epithelial barriers and the resulting systemic inflammation are also important mediators in the pathogenesis of endothelial dysfunction and related organ toxicities, such as capillary leak syndrome and hepatic sinusoidal obstruction syndrome (SOS). 4 A sustained activation of endothelial cells may result in increased capillary permeability, oedema, intravascular hypovolemia, hypercoagulability and decreased organ perfusion. 5 In addition, the activation of sinusoidal endothelial cells leads to the appearance of gaps in the sinusoidal barrier, the initial step in a series of events that result in obstruction of the microcirculation with development of clinical symptoms of SOS. 6, 7 The incidence of SOS is reported to be up to 50-60% in myeloablative conditioning regimens, with the clinical presentation varying from a mild reversible disease to a severe syndrome associated with multi-organ failure and high mortality. 8 Investigation of factors involved in protection and regeneration of epithelial/endothelial tissue may be important in preventing these complications.
Insulin-like growth factor-1 (IGF-1) is a peptide hormone and the primary mediator of the growth-promoting actions of growth hormone. 9 Endogenous IGF-1 is primarily produced by hepatocytes, and is bound to specific IGF binding proteins in the circulation, of which IGF-binding protein 3 (IGFBP-3) is the most abundant. 10 IGFBP-3 promotes the effects of IGF-1 by prolonging its half-life and by modulating transendothelial transport of IGF-1 to target tissues. [10] [11] [12] In addition to its growth-promoting actions, IGF-1 has been shown to promote regeneration of wounded epithelium and attenuate chemotherapy-induced mucositis. [13] [14] [15] Furthermore, IGF-1 has been suggested to inhibit endothelial activation, and is involved in amelioration of endothelial damage. 16, 17 Due to the stabilising effect of IGF-1 on epithelial barriers, we hypothesised that IGF-1 may limit systemic inflammation in patients undergoing HSCT and thereby reduce the risk of toxicities caused by endothelial dysfunction. We measured plasma levels of IGF-1 and IGFBP-3 in patients undergoing HSCT before start of conditioning and during the early post-transplant phase along with levels of inflammatory parameters, and recorded data on the occurrence of fluid retention and SOS.
PATIENTS AND METHODS

Study population
We prospectively recruited 41 patients (age 16.5-55.4 years) undergoing their first myeloablative allogeneic HSCT at Rigshospitalet, Copenhagen from February 2011 to January 2013. Written and oral informed consent was obtained for all patients included. The study was approved by the local ethics committee (H-1-2010-009) and conducted in accordance with the Declaration of Helsinki. Clinical characteristics of the patients are listed in Table 1 , and have previously been reported. 18 Quantification of IGF-1 and IGFBP-3 Blood samples were collected at four time points during HSCT: before initiation of the conditioning regimen (day -7), at the day of transplantation before graft infusion (day 0), and at day +7 and day +21 post transplant. Lithium-heparin anti-coagulated blood was centrifuged shortly after collection, and plasma was isolated and stored at − 80°C o2 h after collection. IGF-1 was dissociated from the binding proteins before quantification. Measurement of IGF-1 and IGFBP-3 concentrations was performed on the IDS-iSYS Multi-Discipline Automated Analyser (Immunodiagnostic Systems LTD, Bolton, UK) using the IDS-iSYS IGF-1 and IDS-iSYS IGFBP-3 assays (Immunodiagnostic Systems LTD, Bolton, UK) based on chemiluminescence technology. These assays have been validated and accredited.
19,20 Plasma levels were converted into age-and sex-adjusted SD-scores (SDS) based on the generalised additive models for location, scale and shape methodology 21 to compensate for age and gender-related differences. Normal ranges were based on data from 3562 healthy children, adolescents and adults. Other aspects of these population studies have previously been published. [22] [23] [24] Plasma levels as well as SD-scores are shown in Supplementary Table 1.
Inflammatory parameters
Plasma from EDTA anti-coagulated blood was collected at day +7 and analysed for Interleukin-6 (IL-6) using the Human Th1/Th2/Th17 Cytometric Bead Array kit and a FACSCalibur flow cytometer (Becton Dickinson and Co., Albertslund, Denmark). This time point was selected due to previous observations of peak IL-6 levels at that stage. 25 Detection limits were 2.5 pg/mL. Levels of C-reactive protein (CRP) were measured daily during hospitalisation using Modular P module (Roche, Basel, Switzerland).
Screening for SOS and fluid retention
Patients were retrospectively evaluated for occurrence of SOS using the modified Seattle criteria. 26, 27 The diagnosis depends on the following criteria, of which two out of three must be present within the first 20 days after transplantation: 42% weight gain from baseline, serum bilirubin 434 μmol/L, and hepatomegaly with right upper quadrant pain. Patients were weighed daily during hospitalisation, and total bilirubin levels were measured along with alanine aminotransferase and international normalised ratio.
Administration of furosemide was used as a measure of fluid retention. None of the patients received other diuretics, and thus data regarding use of furosemide during the first 21 days after transplantation were collected for each patient.
Statistical analyses
Mixed model repeated measures analyses were used for paired comparisons between baseline values of IGF-1 and IGFBP-3 and the subsequent time points. Correlation analyses were performed using Spearman's rank order correlation analysis. The Kruskal-Wallis nonparametric univariate test was used for comparison of continues variables between groups. Logistic multiple regression was used to determine variables associated with occurrence of SOS and aGvHD. Kaplan-Meier estimates with log-rank test for overall survival and cumulative incidence for transplant-related mortality and relapse frequency were determined. A two-sided Po0.05 was considered statistically significant. All statistical analyses were performed using SAS software version 9.4 (SAS Institute, Cary, NC, USA).
RESULTS
IGF-1 and IGFBP-3 during HSCT
The majority of the patients had IGF-1 and IGFBP-3 levels within the normal range (between -2 and 2 SDS) before conditioning, and reduced levels of both mediators were only seen in two (5%) of the patients. IGF-1 rose significantly from a mean value of -0.22 SDS (95% CI: − 0.67 to 0.24) before conditioning to a peak of 0.67 SDS (0.22-1.12, P = 0.0002) at day 0 and then gradually declined towards pre-HSCT levels. In contrast, IGFBP-3 decreased continuously from 0.004 SDS (−0.46 to 0.46) before conditioning towards a mean level of -1.1 SDS (−1.58 to − 0.62, P = 0.0001) at day +21 ( Figure 1 ). Despite the different overall patterns in IGF-1 and IGFBP-3 levels during the course of HSCT, these parameters were positively correlated on each day (r = 0.67-0.74, all Po 0.0001).
To analyse the potential associations between clinical variables and IGF-1 and IGFBP-3, univariate analyses of associations between IGF-1 and IGFBP-3 levels before conditioning and patient characteristics including age, sex, diagnosis, remission status and other transplant characteristics listed in Table 1 were performed. A positive correlation between recipients age and baseline IGF-1 levels were found (r = 0.34, P = 0.006) as the only significant association.
Systemic inflammation
We investigated associations between IGF-1/IGFBP-3 and markers of inflammation including CRP (measured daily) and the pro-inflammatory cytokine IL-6 (measured at day +7). Most patients had normal CRP values before start of conditioning with a median value of 3.6 pg/mL (IQR: 1.4-10.0). CRP peaked about 1 week after transplantation with a median value of 55.2 pg/mL (13.0-117.0) at day +7. 
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IGF-1 levels were inversely correlated with same-day CRP at day 0 (r = − 0.44, P = 0.004) and at day +7 (r = − 0.39, P = 0.011). Similar associations with CRP at day 0 and day +7 were found for IGFBP-3 (r = − 0.70, P o 0.0001 and r = − 0.62, Po 0.0001, respectively). In addition, both IGF-1 and IGFBP-3 levels at day +7 correlated inversely with IL-6 levels at day +7 (r = − 0.40, P = 0.012 and r = − 0.61, P o0.0001, respectively).
Next, we investigated if IGF-1 and IGFBP-3 levels before start of conditioning were predictive of the level of inflammatory markers post HSCT. Patients were stratified in two groups by the median values of IGF-1 and IGFBP-3 before conditioning, and the development in CRP within the first 21 days after transplantation was examined. The group of patients with pre-transplant IGFBP-3-values below the median (o 0.09 SDS) had higher-CRP levels on all days from day +1 to day +21, and this difference was significant from day +1 to day +7 (all P o0.05). Similarly, patients with IGF-1 levels below median value (o − 0.05 SDS) tended to have higher levels of CRP between day +2 and day +19, although not reaching statistical significance (Figure 2 ). No significant associations were found between baseline values of IGF-1 or IGFBP-3 and IL-6 levels at day +7.
Sinusoidal obstruction syndrome In total, 13 of the 41 patients (32%) developed SOS according to the modified Seattle criteria, most of them mildly affected (Table 2) . Median time point of SOS diagnosis was day +9 (range: 1-15). Patients developing SOS had a higher degree of systemic inflammation post HSCT, even before the time point where they fulfilled criteria for SOS, with higher levels of IL-6 at day +7 (median: 41.7 pg/mL (IQR: 15.3-106.6) vs 158.8 pg/mL (88.4-238.3), P = 0.003) and increased levels of CRP during the first 3 weeks post transplant (Figure 3a) .
Associations between levels of IGF-1 and IGFBP-3 in relation to SOS were evaluated. Patients who developed SOS had significantly lower levels of both IGF-1 and IGFBP-3 before start of conditioning (median: − 1.01 SDS (IQR: -1.51 to -0.11) vs 0.30 SDS (−0.65 to 0.76), P = 0.005 and − 0.73 SDS (−1.27 to − 0.27) vs 0.42 SDS (−0.23 to 1.08), P = 0.001, respectively). This was sustained as a trend throughout the course of transplantation, where patients with SOS had lower levels of IGF-1 and IGFBP-3 at day 0 (P = 0.082 and P = 0.007, respectively) and at day +7 (P = 0.023 and P = 0.002; Figure 4) .
The significance of these findings was tested in multivariate analyses adjusted for the use of TBI, cyclophosphamide and busulphan as part of the conditioning regimen, as these have been suggested as the major transplant-related risk factors for developing SOS. 28 In these analyses, low levels of IGF-1 and IGFBP-3 before conditioning remained associated with increased risk of SOS (OR = 5.00 per 1 SDS decrease in IGF-1 (95% CI: 1.45-16.67), P = 0.011 and OR = 5.00 (1.37-20.0), P = 0.015 per 1 SDS decrease in IGFBP-3). Similar patterns were seen in multivariate analyses during the first week post transplant, where odds of developing SOS were increasing with lower levels of IGF-1 and IGFBP-3 at both day 0 and day +7 (all P o0.05). Notably, pre-transplant liver function as measured by levels of alanine aminotransferase, total bilirubin and international normalised ratio was not associated with either IGF-1, IGFBP-3 or development of SOS.
We performed subgroup analyses on patients with more severe SOS, defined by hyperbilirubinemia 434 μmol/L and weight gain 45% (n = 4). With this more limited number of patients, we still found that patients with severe SOS had significantly lower levels of IGF-1 before conditioning as well as at day 0 and at day +7 (all P o 0.05), while SOS patients had lower levels of IGFBP-3 at day 0 (P = 0.031) and at day +7 post transplant (P = 0.035), but not reaching significance with regard to pre-transplant values (P = 0.162).
We evaluated IGF-1 and IGFBP-3 as potential biomarkers of the risk of developing SOS by calculating the sensitivity, specificity, positive-predictive value and negative-predictive value for the best cutoff value for each parameter. For a pre-transplant cutoff value of 0.25 SDS for IGF-1, the sensitivity was 1.00 implying that all of the patients developing SOS had baseline IGF-1 levels below 0.25 SDS, although with modest specificity 0.54. The positivepredictive value was 0.48 while the negative-predictive value was 1.00. Corresponding to this, sensitivity was 0.83 and specificity was 0.79 for an IGFBP-3 cutoff value of -0.25 SDS, with a positivepredictive value of 0.63 and a negative-predictive value of 0.92.
Fluid retention
Seventeen patients received furosemide due to fluid retention within the first 21 days post HSCT. Similar to the SOS patients, patients in need of symptomatic diuretic treatment had higher levels of IL-6 at day +7 (median: 51. 
DISCUSSION
This study investigated associations between plasma levels of IGF-1 and IGFBP-3 in relation to early treatment-related complications following HSCT. Our data indicate that high levels of IGF-1 are associated with reduced levels of pro-inflammatory markers, suggesting a protective effect on systemic inflammation during the early phase after HSCT. Furthermore, we found that high levels of IGF-1 before conditioning were associated with a decreased risk of SOS and a reduced need for symptomatic diuretic treatment.
Existing evidence suggests that IGF-1 and IGFBP-3 may have anti-inflammatory properties by downregulating levels of pro-inflammatory cytokines and by balancing the ratio between pro-and anti-inflammatory cytokines, [29] [30] [31] [32] supporting our findings. In addition, a stabilising effect of IGF-1 on intestinal epithelium could be an explanation for these associations, as chemotherapyinduced disruption of intestinal barriers is considered the primary step in the development of severe systemic inflammatory reactions, including elevated levels of IL-6 and CRP during HSCT. 25, [33] [34] [35] [36] Importantly, this inflammatory response has been associated with increased treatment-related mortality in HSCT. [37] [38] [39] [40] Although our study design does not allow direct insights into any effect of IGF-1 levels on intestinal damage, current evidence suggests a protective role. IGF-1 has previously been investigated as a potential trophic Abbreviations: ALL = acute lymphoblastic leukaemia; AML = acute myeloid leukaemia; BMSC = bone marrow stem cells; BU = busulphan; CY = cyclophosphamide; FLU = fludarabine; MDS = myelodysplastic syndrome; MMUD = HLA-mismatched unrelated donors; MUD = HLA-matched unrelated donors; SIB = HLA-identical siblings; UCB = umbilical cord blood stem cells; VP16 = etoposide.
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factor for intestinal epithelial cells due to its mitogenic and anti-apoptotic effects, and the gastrointestinal tract has been identified as a sensitive target tissue for IGF-I. [41] [42] [43] Furthermore, IGF-1 administration has been shown to protect against radiation and chemotherapy-induced mucositis and to stimulate repair of damaged intestinal cells in the context of burn injuries, inflammatory bowel disease and ulcers. 14, [44] [45] [46] Circulating endotoxins and inflammatory cytokines may also contribute to the development of endothelial dysfunction and early endothelial injury syndromes including SOS, capillary leak syndrome, engraftment syndrome, transplant-related microangiopathy and diffuse alveolar haemorrhage. 4, 6, 47 Our results are consistent with the notion that cytokine release is involved in the pathophysiology of these conditions, as patients developing SOS and fluid retention showed higher levels of CRP and IL-6 post transplant. Current knowledge regarding the pathophysiology of endothelial dysfunction during HSCT is limited, and even though a number of risk factors have been discovered, unknown biological mechanisms may confer increased vulnerability to endothelial dysfunction in some patients. Until now, few risk factors have IGF-1 and SOS after HSCT S Weischendorff et al been discovered besides transplant-associated factors such as myeloablative conditioning regimens and second HSCT. GvHD has also been associated with the risk and severity of the above mentioned endothelial injury syndromes including SOS, and it has been suggested that these conditions share common risk factors (for example, unrelated donors, MHC-mismatches or transplantation with a non-T-cell-depleted graft). 4 Moreover, endothelial cells may be a target for allo-reactive donor cells, which could similarly lead to endothelial activation. In support, biomarkers of endothelial injury are closely related to GvHD. 48 In the present study, severe aGvHD was more frequent in patients with low levels of IGF-1 and IGFBP-3, but in contrast to SOS, these mediators were not predictive for aGvHD. Rather, reduced levels of IGF-1 were seen at the time of manifestation of aGvHD, suggesting that alloreactivity was not the driving mechanism behind the observed association between low IGF-1 and increased risk of SOS.
Hepatic risk factors include elevated transaminases, highly increased serum bilirubin, cirrhosis and active viral hepatitis, which are uncommon before start of treatment. 6, 49 As early intervention with defibrotide is important in patients with SOS, more accurate identification of patients at risk would be of great value and could aid physicians in initiating treatment at an early stage. 50 Furthermore, effective prognostic tools could allow individualised modification of the conditioning regimen to reduce the risk of SOS.
The present study is the first to examine the role of endogenous levels of IGF-1 during HSCT on acute organ toxicities related to endothelial dysfunction. Our results indicate that low levels of IGF-1 and IGFBP-3 before treatment are associated with an increased risk of SOS. Notably, this was irrespective of known risk factors, including pre-transplant liver dysfunction and conditioning with TBI, busulphan and cyclophosphamide. In addition, high levels of IGF-1 and IGFBP-3 were associated with a reduced need for symptomatic diuretic treatment, indicating a lesser degree of capillary leakage. Notably, pre-transplant levels were not influenced by initial pathology (including remission status) or other patient characteristics. Due to the limited size of this study we cannot fully exclude underlying associations, and further studies are needed to address this question.
IGF-1 has previously been suggested to be an inhibitor of endothelial activation and as a protective factor against endothelial damage, through direct effects on the endothelium and as a mediator of endothelial regeneration through stimulation of existent endothelial progenitor cells. 16, 17 Endothelial progenitor cells contribute to angiogenesis and are part of a vascular repair system under pathological conditions. 51 IGF-1 increases endothelial nitric oxide synthase activity and levels of circulating endothelial progenitor cells with multiple beneficial effects including antioxidant and vascular protective effects, and IGF-1 may favour endothelial regeneration at sites of tissue damage. 16, 17, 52, 53 In addition, IGF-1 can counteract endothelial dysfunction through its anti-apoptotic and anti-inflammatory properties, 52 an effect that may also influence the risk of severe aGvHD in patients with low IGF-1 levels. Thus, our results support existing evidence of IGF-1 as a vascular protective factor.
In this study we employed the modified Seattle criteria, which have been criticised for their relatively low specificity. 6 To compensate for these shortcomings, we performed subgroup analyses on patients with hyperbilirubinemia 434 μmol/L and weight gain 45%. Our results were confirmed in these patients with more severe SOS, but further studies should investigate these findings in a larger cohort. New criteria for the diagnosis of SOS are currently being introduced. 54 Evaluation of IGF-1 and IGFBP-3 levels in relation to SOS as defined by the new criteria would be of great value.
We performed statistical evaluation of IGF-1 and IGFBP-3 as possible biomarkers to detect patients at risk of developing SOS. These calculations suggested that development of SOS is infrequent in patients with IGF-1 levels above 0.25 SDS and IGFBP-3 levels above − 0.25, but the clinical utility is challenged by a large number of false positive cases. These observations must be taken with considerable reservation due to the limited number of patients in the study.
Our results also raise the question of whether prophylactic treatment with IGF-1 in patients with low plasma levels before transplantation could limit early toxicities, including SOS. Recombinant human (rh) IGF-1 has previously been examined as a possible treatment to improve outcome after severe epithelial damage, but adverse events such as hypoglycaemia and electrolyte imbalances have complicated its use. 55 However, administration of low doses of rhIGF-1 in combination with IGFBP-3 after burn injuries has shown promising results on attenuation of acute phase reactions without unwanted side effects. 30 An important concern, however, is the safety in a neoplastic setting. Nearly all haematopoietic cells express IGF receptors, and IGF-1 is a mitogenic factor in erythropoiesis, granulopoiesis and lymphopoiesis. 56 It may be speculated that supplementation of IGF-1 could be a potential therapeutic approach in patients with low baseline levels of IGF-1 and IGFBP-3 or in patients transplanted for benign disease. In our relatively small cohort we did not see any association between IGF-1 levels and relapse frequency, but further studies are needed to address these considerations regarding clinical utility.
In conclusion, our findings suggest that high levels of IGF-1 and IGFBP-3 may reduce the risk of SOS and protect against fluid retention, possibly by attenuating mucosal and endothelial damage and toxic inflammatory reactions caused by chemotherapy. The clinical use of IGF-1 and IGFBP-3 as biomarkers for early identification of patients at risk of SOS merits further investigation and could potentially guide individualised modifications of conditioning regimens and the use of defibrotide in HSCT.
